Chengdu Celincare Biotechnology

Chengdu Celincare Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the discovery and development of novel small molecule drugs. The company's research efforts are primarily concentrated on oncology and inflammatory conditions, utilizing a precision medicine approach to target specific molecular drivers of disease. Its lead asset, CT-707 (conteltinib), is a multi-kinase inhibitor with potent activity against Focal Adhesion Kinase (FAK) and is currently being evaluated in Phase 2 trials for non-small cell lung cancer. Celincare's broader pipeline includes inhibitors for KRAS G12D and BTK, as well as TLR7/8 agonists, positioning the company as a significant player in the Chinese innovative drug landscape. The firm was founded by industry veterans with extensive experience in global pharmaceutical R&D, aiming to bridge the gap between basic science and clinical application.